Occasional review: influenza in COPD: pathogenesis, prevention, and treatment.

The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One (2013) 1.19

Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One (2010) 1.01

NKG2D mediates NK cell hyperresponsiveness and influenza-induced pathologies in a mouse model of chronic obstructive pulmonary disease. J Immunol (2012) 0.94

Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ont Health Technol Assess Ser (2012) 0.86

Effectiveness of the influenza vaccine at preventing hospitalization due to acute exacerbation of cardiopulmonary disease in Korea from 2011 to 2012. Hum Vaccin Immunother (2013) 0.82

A novel lung explant model for the ex vivo study of efficacy and mechanisms of anti-influenza drugs. J Immunol (2015) 0.80

The influence of virus infections on the course of COPD. Eur J Microbiol Immunol (Bp) (2012) 0.77

The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India. Virusdisease (2016) 0.75

Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ (2000) 8.53

Neuraminidase inhibitors for influenza. N Engl J Med (2005) 7.79

Clinical signs and symptoms predicting influenza infection. Arch Intern Med (2000) 5.83

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care (2001) 5.61

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med (1995) 5.21

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 5.17

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38

The impact of influenza epidemics on hospitalizations. J Infect Dis (2000) 4.28

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02

Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis (2006) 3.74

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol (2004) 3.43

Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother (2003) 3.24

Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res (2001) 2.91

Influenza: diagnosis, management, and prophylaxis. BMJ (1994) 2.49

Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax (2003) 2.33

Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med (1998) 2.03

Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest (2004) 1.89

Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev (2006) 1.89

Influenza vaccines. Wkly Epidemiol Rec (2005) 1.87

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res (2000) 1.81

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med (1999) 1.80

Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) 1.78

Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis (1966) 1.54

Epidemiology and pathogenesis of influenza. J Antimicrob Chemother (1999) 1.52

Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2004) 1.51

How viral infections cause exacerbation of airway diseases. Chest (2006) 1.48

Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40

Zanamivir: a review of clinical safety. Drug Saf (1999) 1.20

Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2006) 1.13

Influenza. Infect Dis Clin North Am (2000) 1.10

Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest (2006) 0.92

Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med (2002) 0.81

Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2004) 0.79

Management of influenza in patients with asthma or chronic obstructive pulmonary disease. Ann Allergy Asthma Immunol (2001) 0.79